Replies to post #161057 on Biotech Values

[genisi]

I don't have access to the full paper but from the summary I see that the study demonstrated the CCP score was a significant predictor of disease outcome for both cohorts (the USA and UK) :

Findings
After prostatectomy, the CCP score was useful for predicting biochemical recurrence in the univariate analysis (hazard ratio for a 1-unit change [doubling] in CCP 1·89; 95% CI 1·54—2·31; p=5·6×10-9) and the best multivariate analysis (1·77, 1·40—2·22; p=4·3×10-6). In the best predictive model (final multivariate analysis), the CCP score and prostate-specific antigen (PSA) concentration were the most important variables and were more significant than any other clinical variable. In the TURP cohort, the CCP score was the most important variable for prediction of time to death from prostate cancer in both univariate analysis (2·92, 2·38—3·57, p=6·1×10-22) and the final multivariate analysis (2·57, 1·93—3·43; p=8·2×10-11), and was stronger than all other prognostic factors, although PSA concentration also added useful information. Heterogeneity in the hazard ratio for the CCP score was not noted in any case for any clinical variables.

Note that these are just the first 2 cohorts and there are 7 more plus the most important one - a prospective study.